Jacobs Levy Equity Management
IMGN

Jacobs Levy Equity Management’s Immunogen Inc IMGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-94,826
Closed -$451K – 1118
2022
Q1 		$451K Sell
94,826
-42,748
-31% -$237K ﹤0.01% 876
2021
Q4 		$1.02M Buy
137,574
+94,150
+217% +$585K 0.01% 735
2021
Q3 		$246K Sell
43,424
-29,905
-41% -$173K ﹤0.01% 958
2021
Q2 		$483K Buy
73,329
+29,905
+69% +$209K ﹤0.01% 867
2021
Q1 		$352K Sell
43,424
-293,429
-87% -$2.4M ﹤0.01% 916
2020
Q4 		$2.17M Buy
336,853
+20,752
+7% +$121K 0.02% 568
2020
Q3 		$1.14M Sell
316,101
-208,336
-40% -$841K 0.01% 636
2020
Q2 		$2.41M Sell
524,437
-37,193
-7% -$158K 0.03% 487
2020
Q1 		$1.92M Sell
561,630
-16,384
-3% -$71.6K 0.02% 482
2019
Q4 		$2.95M Buy
578,014
+152,016
+36% +$516K 0.03% 472
2019
Q3 		$1.03M Buy
425,998
+305,698
+254% +$812K 0.01% 611
2019
Q2 		$261K Sell
120,300
-168,840
-58% -$399K ﹤0.01% 835
2019
Q1 		$784K Buy
289,140
+735
+0.3% +$3.18K 0.01% 709
2018
Q4 		$1.38M Buy
288,405
+85,198
+42% +$517K 0.02% 539
2018
Q3 		$1.92M Sell
203,207
-22,657
-10% -$218K 0.03% 529
2018
Q2 		$2.2M Buy
225,864
+42,530
+23% +$448K 0.03% 491
2018
Q1 		$1.93M Sell
183,334
-169,190
-48% -$1.67M 0.03% 490
2017
Q4 		$2.26M Buy
352,524
+15,500
+5% +$95.6K 0.04% 430
2017
Q3 		$2.58M Sell
337,024
-13,610
-4% -$90.4K 0.05% 381
2017
Q2 		$2.49M Buy
+350,634
New +$1.6M 0.05% 379
2016
Q4 		– Sell
-209,500
Closed -$561K – 1076
2016
Q3 		$561K Sell
209,500
-126,100
-38% -$367K 0.01% 696
2016
Q2 		$1.03M Buy
335,600
+109,700
+49% +$688K 0.02% 582
2016
Q1 		$1.93M Buy
225,900
+191,200
+551% +$1.62M 0.04% 417
2015
Q4 		$471K Buy
34,700
+20,200
+139% +$249K 0.01% 561
2015
Q3 		$139K Sell
14,500
-133,728
-90% -$1.95M ﹤0.01% 736
2015
Q2 		$2.13M Sell
148,228
-48,200
-25% -$529K 0.04% 369
2015
Q1 		$1.76M Buy
+196,428
New +$1.42M 0.03% 385

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jacobs Levy Equity Management's IMGN Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Immunogen Inc (IMGN) in Q2 2022, closing a stake of 94,826 shares — an estimated $451K sold.

Jacobs Levy Equity Management first reported a position in IMGN in Q1 2015 and held it in 27 quarters. The position peaked at $2.95M in Q4 2019. 216 funds tracked by Wall St. Rank hold IMGN as of Q2 2022.

  • Jacobs Levy Equity Management reported no remaining Immunogen Inc position as of Q2 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 94,826 Immunogen Inc shares in Q2 2022, an estimated $451K.
  • Jacobs Levy Equity Management first reported a position in Immunogen Inc in Q1 2015 and held it in 27 quarters.
  • Jacobs Levy Equity Management's Immunogen Inc position peaked at $2.95M in Q4 2019.
  • 216 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.